NCT04451954View on ClinicalTrials.gov

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

September 20, 2021

Study Completion Date

September 20, 2021

Conditions
Influenza ImmunisationHealthy Volunteers
Interventions
BIOLOGICAL

Quadrivalent RIV with H3 strain 1

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 1 and adjuvant

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 2

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 2 and adjuvant

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with 2018-2019 NH H3 strain

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Trial Locations (5)

20850

Investigational Site Number 8400005, Rockville

32806

Investigational Site Number 8400004, Orlando

32934

Investigational Site Number 8400002, Melbourne

61614

Investigational Site Number 8400001, Peoria

92108

Investigational Site Number 8400003, San Diego

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04451954 - Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter